Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib
In this international non-interventional study safety and clinical data concerning the treatment of patients suffering from Hepatocellular Carcinoma (HCC) will be collected.
Carcinoma, Hepatocellular
DRUG: Sorafenib (Nexavar, BAY43-9006)
The safety of Nexavar in all patients with unresectable HCC who are candidates for systemic therapy and in whom a decision to treat with Nexavar has been made under real-life practice conditions, at each follow-up visit, every 2-4 months on average
Efficacy [overall survival (OS), progression-free survival (PFS), time to progression (TTP), response rate (RR), stable disease(SD) rate] by the Response Evaluation Criteria in Solid Tumor (RECIST) Criteria of Nexavar, at every visit, roughly every 2-4 months|The duration of therapy with Nexavar in a variety of settings according to patient characteristics and other variables, at every visit, roughly every 2-4 months|To evaluate the methods of patient evaluation, diagnosis and follow up, at every visit, roughly every 2-4 months|To evaluate the co-morbidities in patients with unresectable HCC and their influence on treatment and outcome, at every visit, roughly every 2-4 months|To evaluate the practice patterns of the physicians involved in the care of patients with HCC under real-life conditions, at every visit, roughly every 2-4 months|Reports of adverse events, at every visit, roughly every 2-4 months
In this international non-interventional study safety and clinical data concerning the treatment of patients suffering from Hepatocellular Carcinoma (HCC) will be collected.